Pegfilgrastim reduces the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Lupin has entered into a license, supply and technology sharing agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the Middle East region operating through its pharmaceutical
subsidiaries; Pharma International Company and Med City Pharmaceutical Industries. Under the terms of the agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim drug products in
certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.
Lupin had earlier received the US FDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
